Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance]).
Yoon HH, Ou FS, Soori GS, Shi Q, Wigle DA, Sticca RP, Miller RC, Leenstra JL, Peller PJ, Ginos B, Heying E, Wu TT, Drevyanko TF, Ko S, Mattar BI, Nikcevich DA, Behrens RJ, Khalil MF, Kim GP, Alberts SR. Yoon HH, et al. Among authors: ginos b. Eur J Cancer. 2021 Jun;150:214-223. doi: 10.1016/j.ejca.2021.03.025. Epub 2021 Apr 29. Eur J Cancer. 2021. PMID: 33934058 Free PMC article. Clinical Trial.
Reliability and validity of PRO-CTCAE® daily reporting with a 24-hour recall period.
Lee MK, Basch E, Mitchell SA, Minasian LM, Langlais BT, Thanarajasingam G, Ginos BF, Rogak LJ, Mendoza TR, Bennett AV, Schrag D, Mazza GL, Dueck AC. Lee MK, et al. Among authors: ginos bf. Qual Life Res. 2023 Jul;32(7):2047-2058. doi: 10.1007/s11136-023-03374-5. Epub 2023 Mar 10. Qual Life Res. 2023. PMID: 36897529 Free PMC article.
Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma.
Ma DJ, Price KA, Moore EJ, Patel SH, Hinni ML, Garcia JJ, Graner DE, Foster NR, Ginos B, Neben-Wittich M, Garces YI, Chintakuntlawar AV, Price DL, Olsen KD, Van Abel KM, Kasperbauer JL, Janus JR, Waddle M, Miller R, Shiraishi S, Foote RL. Ma DJ, et al. Among authors: ginos b. J Clin Oncol. 2019 Aug 1;37(22):1909-1918. doi: 10.1200/JCO.19.00463. Epub 2019 Jun 4. J Clin Oncol. 2019. PMID: 31163012 Free PMC article. Clinical Trial.
Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048.
Basch E, Dueck AC, Rogak LJ, Mitchell SA, Minasian LM, Denicoff AM, Wind JK, Shaw MC, Heon N, Shi Q, Ginos B, Nelson GD, Meyers JP, Chang GJ, Mamon HJ, Weiser MR, Kolevska T, Reeve BB, Bruner DW, Schrag D. Basch E, et al. Among authors: ginos b. J Clin Oncol. 2018 Sep 11;36(31):JCO2018788620. doi: 10.1200/JCO.2018.78.8620. Online ahead of print. J Clin Oncol. 2018. PMID: 30204536 Free PMC article.
Long-Term Toxic Effects, Swallow Function, and Quality of Life on MC1273: A Phase 2 Study of Dose De-escalation for Adjuvant Chemoradiation in Human Papillomavirus-Positive Oropharyngeal Cancer.
Price K, Van Abel KM, Moore EJ, Patel SH, Hinni ML, Chintakuntlawar AV, Graner D, Neben-Wittich M, Garces YI, Price DL, Janus JR, Foster NR, Ginos BF, Foote RL, Ma D. Price K, et al. Among authors: ginos bf. Int J Radiat Oncol Biol Phys. 2022 Oct 1;114(2):256-265. doi: 10.1016/j.ijrobp.2022.05.047. Epub 2022 Jun 5. Int J Radiat Oncol Biol Phys. 2022. PMID: 35675850 Free article. Clinical Trial.
Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048).
Basch E, Dueck AC, Mitchell SA, Mamon H, Weiser M, Saltz L, Gollub M, Rogak L, Ginos B, Mazza GL, Colgrove B, Chang G, Minasian L, Denicoff A, Thanarajasingam G, Musher B, George T, Venook A, Farma J, O'Reilly E, Meyerhardt JA, Shi Q, Schrag D. Basch E, et al. Among authors: ginos b. J Clin Oncol. 2023 Jul 20;41(21):3724-3734. doi: 10.1200/JCO.23.00903. Epub 2023 Jun 4. J Clin Oncol. 2023. PMID: 37270691 Clinical Trial.
A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma.
Padrnos L, Ernst B, Dueck AC, Kosiorek HE, Ginos BF, Toro A, Johnston PB, Habermann TM, Leis JF, Mikhael JR, Nowakowski GS, Colgan J, Porrata L, Ansell SM, Witzig TE, Reeder C. Padrnos L, et al. Among authors: ginos bf. Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):664-672.e2. doi: 10.1016/j.clml.2018.06.013. Epub 2018 Jun 15. Clin Lymphoma Myeloma Leuk. 2018. PMID: 30104176 Clinical Trial.
Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial.
Basch E, Schrag D, Henson S, Jansen J, Ginos B, Stover AM, Carr P, Spears PA, Jonsson M, Deal AM, Bennett AV, Thanarajasingam G, Rogak LJ, Reeve BB, Snyder C, Bruner D, Cella D, Kottschade LA, Perlmutter J, Geoghegan C, Samuel-Ryals CA, Given B, Mazza GL, Miller R, Strasser JF, Zylla DM, Weiss A, Blinder VS, Dueck AC. Basch E, et al. Among authors: ginos b. JAMA. 2022 Jun 28;327(24):2413-2422. doi: 10.1001/jama.2022.9265. JAMA. 2022. PMID: 35661856 Free PMC article. Clinical Trial.
28 results